CAR T Glioblastoma Therapy Wins China Patent Nod

Elicera's ELC-401 patent runs to 2041 as the research-stage therapy targets an aggressive brain tumor.

Updated on Nov. 5, 2026 in Biotech

Frosted steel cryogenic rack holding sealed glass vials, with cold vapor rising from one open vial against a dark laboratory surface.
China's National Intellectual Property Administration has allowed a patent for Elicera Therapeutics' ELC-401, a CAR T-cell therapy for glioblastoma that remains in research. AI Illustration. Upload story photo >

China's National Intellectual Property Administration has issued a notice of allowance for a patent application covering ELC-401, a CAR T-cell therapy for glioblastoma developed by Elicera Therapeutics. The patent is expected to be formally granted shortly and would provide protection until 2041. The therapy remains research-stage; this is a patent milestone, not an approved treatment.

Why it matters

The allowance extends Elicera's intellectual property position for ELC-401 into China, following corresponding applications already allowed in the United States and granted in Japan. It signals the company is building multi-jurisdiction protection for a CAR T approach aimed at IL13Rα2-positive tumors, in a field where glioblastoma's poor prognosis has drawn sustained research investment.

The evidence here is a patent allowance, not clinical data, and the filing reports a protection term running to 2041 against a standard-of-care median survival of about 15 months for glioblastoma. No measured efficacy or safety figures for ELC-401 are provided in the source, and whether the therapy outperforms that baseline remains unestablished.

The players

Elicera Therapeutics

Uppsala, Sweden-based biotech developing CAR T-cell therapies, including ELC-401 and the iTANK immune-stimulation platform.

China National Intellectual Property Administration

China's national patent office, which issued the notice of allowance for the ELC-401 application.

The details

ELC-401 is a CAR T-cell therapy, meaning a patient's own immune T-cells are engineered to recognize and attack cancer cells. The patented component binds to the protein IL-13Rα2, which is expressed on many glioblastoma tumors. The therapy pairs this targeting with Elicera's iTANK platform, designed to stimulate the body's own immune responses against the tumor rather than relying solely on the engineered cells.

Timeline

  1. November 5, 2026: China's National Intellectual Property Administration announced the notice of allowance for the ELC-401 patent.

  2. 2041: Protection under the Chinese patent is set to expire.

The Tech Race

CAR T-cell therapy has its clearest clinical track record in blood cancers, and Elicera's ELC-401 patent extends that engineered-cell approach toward glioblastoma, a solid brain tumor with a median survival of roughly 15 months. Patent allowances in China, the United States and Japan position the company to compete in this harder-to-treat indication.

Patients with glioblastoma are not affected by this filing yet, since ELC-401 is research-stage and no availability or pricing has been announced. The patent allowance matters for the timeline only insofar as it protects the therapy's commercial development in China until 2041.

The takeaway

Watch for the formal grant of the Chinese ELC-401 patent, which the source expects shortly. Clinical data for ELC-401 would be the next meaningful signal of whether the approach can extend glioblastoma survival beyond the roughly 15-month standard.

Further reading

For more on the research behind engineered immune cells, browse our Biotech coverage.

Source note: This article includes information reported by Firstwordpharma.